Showing results (11-20 of 65) with videos related to
Sort By:
Pageof 7
Neuroscience Letters|September 13, 2005
Activator of G protein signaling type 3 mRNA is widely distributed in the rat brain and is particularly abundant in the subventricular zone-olfactory bulb system of neural precursor cell proliferation, migration and differentiationJean-Marc Taymans, Hossein Kami Kia, Xavier LangloisJournal of Neurochemistry|June 15, 2006
Distribution of PINK1 and LRRK2 in rat and mouse brainJean-Marc Taymans, Chris Van den Haute, Veerle BaekelandtBioorganic & Medicinal Chemistry Letters|September 16, 2014
Indolinone based LRRK2 kinase inhibitors with a key hydrogen bondStefan Göring, Jean-Marc Taymans, Veerle Baekelandt, et al.Trends in Molecular Medicine|June 21, 2015
Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson's disease pathogenesisJean-Marc Taymans, Aurore Nkiliza, Marie-Christine Chartier-HarlinCells|April 30, 2021
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient CellsLiesel Goveas, Eugénie Mutez, Marie-Christine Chartier-Harlin, et al.Cells|September 28, 2021
Alpha-Synuclein and Lipids: The Elephant in the Room?Alessia Sarchione, Antoine Marchand, Jean-Marc Taymans, et al.CNS & Neurological Disorders Drug Targets|August 16, 2011
Kinases as targets for Parkinson's disease: from genetics to therapyRenee Vancraenenbroeck, Evy Lobbestael, Marc De Maeyer, et al.Neuroreport|January 27, 2005
MK-801 alters RGS2 levels and adenylyl cyclase sensitivity in the rat striatumJean-Marc Taymans, Catarina Cruz, Anne Lesage, et al.Bioscience Reports|September 25, 2020
Pathogenic LRRK2 requires secondary factors to induce cellular toxicityEvy Lobbestael, Chris Van den Haute, Francesca Macchi, et al.Biochemical Society Transactions|February 17, 2017
LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?Jean-Marc Taymans, Eugénie Mutez, Matthieu Drouyer, et al.Pageof 7